Arvin C. Dar

Arvin C. Dar

Auto-generated profile, based on publicly available information

Arvin C. Dar

Program in Chemical Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
ZKZaigham M. Khan
Zaigham M. Khan
ARAlexander M. Real
Alexander M. Real
WMWilliam M. Marsiglia
William M. Marsiglia
ACArthur Chow
Arthur Chow
MDMary E. Duffy
Mary E. Duffy
ADArvin C. Dar
Arvin C. Dar

24 August 2016 in Nature
Verified
Journal Article
Open access
PDF file
NDNeil S. Dhawan
Neil S. Dhawan
ASAlex P. Scopton
Alex P. Scopton
ADArvin C. Dar
Arvin C. Dar
Deregulation of the Ras–mitogen activated protein kinase (MAPK) pathway is an early event in many different cancers and a key driver of resistance to targeted therapies1. Sustained signalling through this pathway is caused most often by mutations in K-Ras, which biochemically favours the stabilization of active RAF signalling complexes2. Kinase suppressor of Ras (KSR) is a MAPK scaffold3,4,5 that is subject to allosteric regulation through dimerization with RAF6,7. Direct targeting of KSR could have important therapeutic implications for cancer; however, testing this hypothesis has been difficult owing to a lack of small-molecule antagonists of KSR function. Guided by KSR mutations that selectively suppress oncogenic, but not wild-type, Ras signalling, we developed a class of compounds that stabilize a previously unrecognized inactive state of KSR. These compounds, exemplified by APS-2-79, modulate KSR-dependent MAPK signalling by antagonizing RAF heterodimerization as well as the conformational changes required for phosphorylation and activation of KSR-bound MEK (mitogen-activated protein kinase kinase). Furthermore, APS-2-79 increased the potency of several MEK inhibitors specifically within Ras-mutant cell lines by antagonizing release of negative feedback signalling, demonstrating the potential of targeting KSR to improve the efficacy of current MAPK inhibitors. These results reveal conformational switching in KSR as a druggable regulator of oncogenic Ras, and further suggest co-targeting of enzymatic and scaffolding activities within Ras–MAPK signalling complexes as a therapeutic strategy for overcoming Ras-driven cancers.

22 January 2018 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
MSMasahiro Sonoshita
Masahiro Sonoshita
ASAlex P Scopton
Alex P Scopton
PUPeter M U Ung
Peter M U Ung
MMMatthew A Murray
Matthew A Murray
LSLisa Silber
Lisa Silber
ADArvin C Dar
Arvin C Dar

24 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
RSRyan H.B. Smith
Ryan H.B. Smith
ADArvin C. Dar
Arvin C. Dar
ASAvner Schlessinger
Avner Schlessinger
Motivation: Binding pocket volumes are a simple yet important predictor of small molecule binding; however, generating visualizations of pocket topology and performing meaningful volume comparisons can be difficult with available tools. Current programs for accurate volume determination rely on extensive user input to define bulk solvent boundaries and to partition cavities into subpockets, increasing inter-user variability in measurements as well as time demands.Results: We developed PyVOL, a python package with a PyMOL interface and GUI, to visualize, to characterize, and to compare binding pockets. PyVOL’s pocket identification algorithm is designed to maximize reproducibility through minimization of user-provided parameters, avoidance of grid-based methods, and automated subpocket identification. This approach permits efficient, scalable volume calculations.Availability: PyVOL is released under the MIT License. Source code and documentation are available through github (https://github.com/schlessingerlab/pyvol/) with distribution through PyPI (bio-pyvol).Contact: avner.schlessinger@mssm.edu, arvin.dar@mssm.edu

19 April 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MRMeagan B. Ryan
Meagan B. Ryan
BQBradley Quade
Bradley Quade
NSNatasha Schenk
Natasha Schenk
ZFZhong Fang
Zhong Fang
MZMarshall Zingg
Marshall Zingg
MHMargit Hagel
Margit Hagel
Alterations in the RAS–MAPK signaling cascade are common across multiple solid tumor types and are a driver for many cancers. NST-628 is a potent pan-RAF–MEK molecular glue that prevents the phosphorylation and activation of MEK by RAF, overcoming the limitations of traditional RAS–MAPK inhibitors and leading to deep durable inhibition of the pathway. Cellular, biochemical, and structural analyses of RAF–MEK complexes show that NST-628 engages all isoforms of RAF and prevents the formation of BRAF–CRAF heterodimers, a differentiated mechanism from all current RAF inhibitors. With a potent and durable inhibition of the RAF–MEK signaling complex as well as high intrinsic permeability into the brain, NST-628 demonstrates broad efficacy in cellular and patient-derived tumor models harboring diverse MAPK pathway alterations, including orthotopic intracranial models. Given its functional and pharmacokinetic mechanisms that are differentiated from previous therapies, NST-628 is positioned to make an impact clinically in areas of unmet patient need. Significance: This study introduces NST-628, a molecular glue having differentiated mechanism and drug-like properties. NST-628 treatment leads to broad efficacy with high tolerability and central nervous system activity across multiple RAS- and RAF-driven tumor models. NST-628 has the potential to provide transformative clinical benefits as both monotherapy and vertical combination anchor.

13 June 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MSMegan Schwarz
Megan Schwarz
DTDenis Torre
Denis Torre
DODaniel Lozano Ojalvo
Daniel Lozano Ojalvo
ATAnthony T. Tan
Anthony T. Tan
TTTommaso Tabaglio
Tommaso Tabaglio
Ernesto GuccioneErnesto Guccione
Ernesto Guccione